PANKREASRAUMFORDERUNG E10-E14 C25
Conditions
Interventions
Group 1: In this study, a blood test for exclusion of pancreatic cancer will be developed in high-risk groups. This risk group includes people with a chronic inflammation of the pancreas, newly diagno
Sponsors
LMU Klinikum
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with solid pancreatic mass lesion on imaging (abdominal CT), which requires further diagnostics (including patients with newly diagnosed diabetes (DM), familial PDAC and chronic pancreatitis (CP) OR diagnosis of diabetes over the age of 50 years
Exclusion criteria
Exclusion criteria: inability to give informed consent, pregnant or breastfeeding women, conditions precluding surgery, biopsy or clinical follow-up justify exclusion from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of the study is the exclusion of a pancreatic cancer with high specificity in a cohort with an increased risk of pancreatic cancer and the highest possible diagnostic accuracy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are a confirmed/excluded cancerous or precancerous lesions of the pancreas by imaging, histology or a minimum of 24 months follow up. Effect of tumour subtype, grading or staging (TNM), medication, dyslipidemia, thyroid dysfunction, renal insufficiency or associated diseases on MxP®PancreasScore shall be examined as well as changes in MxP®PancreasScore under treatment and during progression. | — |
Countries
Germany
Contacts
Public ContactJulia Mayerle
Medizinische Klinik 2 der LMU München
Outcome results
None listed